These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29199359)

  • 1. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
    Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
    Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Álvarez-Gutiérrez A; Montero-Corominas D
    Bone; 2017 Dec; 105():292-298. PubMed ID: 28890137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larranaga S; Sami A; Hawley S; Judge A; Arden N; Van Staa TP; Cooper C; Abrahamsen B; Javaid MK; Prieto-Alhambra D
    Osteoporos Int; 2022 Jul; 33(7):1579-1589. PubMed ID: 35138412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
    Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
    Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database.
    Breart G; Cooper C; Meyer O; Speirs C; Deltour N; Reginster JY
    Osteoporos Int; 2010 Jul; 21(7):1181-7. PubMed ID: 19806285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study.
    Martín-Merino E; Calderón-Larrañaga A; Hawley S; Poblador-Plou B; Llorente-García A; Petersen I; Prieto-Alhambra D
    Clin Epidemiol; 2018; 10():643-654. PubMed ID: 29892204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Related Adverse Events of Osteoporosis Therapy.
    Khan M; Cheung AM; Khan AA
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
    Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
    Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance.
    Ali MS; Berencsi K; Marinier K; Deltour N; Perez-Guthann S; Pedersen L; Rijnbeek P; Lapi F; Simonetti M; Reyes C; Van der Lei J; Sturkenboom M; Prieto-Alhambra D
    Osteoporos Int; 2020 Dec; 31(12):2425-2438. PubMed ID: 32757044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
    Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
    Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
    Svanström H; Pasternak B; Hviid A
    Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
    Cooper C; Fox KM; Borer JS
    Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea.
    Park SY; Kim SH; Kim TY; Lee YK; Ha YC; Jang S; Ahn SH; Kim HY
    J Korean Med Sci; 2021 Jul; 36(27):e186. PubMed ID: 34254473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.